Dynavax Technologies Corp

詳細情報 Dynavax Technologies Corp 企業名

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

企業情報

企業コードDVAX

会社名Dynavax Technologies Corp

上場日Feb 19, 2004

最高経営責任者「CEO」Mr. Ryan Spencer

従業員数405

証券種類Ordinary Share

決算期末Feb 19

本社所在地2100 Powell Street

都市EMERYVILLE

証券取引所NASDAQ Global Select Consolidated

国United States of America

郵便番号94608

電話番号15108485100

ウェブサイトhttps://www.dynavax.com/

企業コードDVAX

上場日Feb 19, 2004

最高経営責任者「CEO」Mr. Ryan Spencer

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Ryan Spencer

Chief Executive Officer, Director

277.67K

--

Dr. Robert (Rob) Janssen, M.D.

Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs

74.92K

--

Mr. David F. Novack

President, Chief Operating Officer

56.05K

+33.36%

Mr. John L. Slebir

Senior Vice President, General Counsel

31.42K

--

Ms. Elaine D. Sun

Independent Director

29.86K

+23.89%

Ms. Kelly MacDonald, CPA

Chief Financial Officer, Senior Vice President

25.52K

--

Dr. Peter R. Paradiso, Ph.D.

Independent Director

24.83K

+30.19%

Dr. Daniel L. (Dan) Kisner, M.D.

Independent Director

23.33K

+32.77%

Mr. Brent MacGregor

Independent Director

21.83K

+35.83%

Dr. Emilio Emini

Independent Director

1.44K

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Ryan Spencer

Chief Executive Officer, Director

277.67K

--

Dr. Robert (Rob) Janssen, M.D.

Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs

74.92K

--

Mr. David F. Novack

President, Chief Operating Officer

56.05K

+33.36%

Mr. John L. Slebir

Senior Vice President, General Counsel

31.42K

--

Ms. Elaine D. Sun

Independent Director

29.86K

+23.89%

Ms. Kelly MacDonald, CPA

Chief Financial Officer, Senior Vice President

25.52K

--

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

事業別USD

会社名

収益

比率

HEPLISAV-B

64.96M

95.30%

Other revenue

3.21M

4.70%

地域別USD

会社名

収益

比率

US

67.81M

99.47%

Non-US

358.00K

0.53%

事業別

地域別

事業別USD

会社名

収益

比率

HEPLISAV-B

64.96M

95.30%

Other revenue

3.21M

4.70%

株主

更新時刻: Sat, May 17

株主統計

種類

株主統計

比率

BlackRock Institutional Trust Company, N.A.

15.53%

Deep Track Capital LP

14.82%

The Vanguard Group, Inc.

7.22%

State Street Global Advisors (US)

5.65%

Tang Capital Management, LLC

4.79%

Other

51.99%

株主統計

比率

BlackRock Institutional Trust Company, N.A.

15.53%

Deep Track Capital LP

14.82%

The Vanguard Group, Inc.

7.22%

State Street Global Advisors (US)

5.65%

Tang Capital Management, LLC

4.79%

Other

51.99%

種類

株主統計

比率

Investment Advisor

40.52%

Hedge Fund

38.07%

Investment Advisor/Hedge Fund

21.73%

Research Firm

5.56%

Pension Fund

1.34%

Individual Investor

0.59%

Sovereign Wealth Fund

0.57%

Bank and Trust

0.55%

Venture Capital

0.06%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

551

130.99M

109.09%

-16.02M

2025Q1

575

132.57M

110.30%

-15.70M

2024Q4

565

133.92M

107.04%

-18.98M

2024Q3

561

132.88M

101.45%

-18.82M

2024Q2

547

135.21M

103.33%

-14.69M

2024Q1

545

136.49M

104.51%

-4.07M

2023Q4

529

128.50M

99.42%

-9.47M

2023Q3

515

128.65M

99.89%

-9.14M

2023Q2

503

129.32M

100.65%

-12.27M

2023Q1

497

129.65M

101.54%

-1.28M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

BlackRock Institutional Trust Company, N.A.

18.65M

15.53%

-799.41K

-4.11%

Mar 31, 2025

Deep Track Capital LP

17.79M

14.82%

--

Mar 31, 2025

The Vanguard Group, Inc.

8.67M

7.22%

-459.90K

-5.04%

Mar 31, 2025

State Street Global Advisors (US)

6.79M

5.65%

-1.00M

-12.88%

Mar 31, 2025

Tang Capital Management, LLC

5.75M

4.79%

+3.90M

+210.81%

Mar 31, 2025

Chicago Capital, LLC

5.34M

4.45%

-36.81K

-0.68%

Mar 31, 2025

Deerfield Management Company, L.P.

5.19M

4.32%

-2.33K

-0.04%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

4.01M

3.34%

-58.27K

-1.43%

Mar 31, 2025

Geode Capital Management, L.L.C.

3.07M

2.55%

+71.47K

+2.39%

Mar 31, 2025

Renaissance Technologies LLC

2.71M

2.25%

+350.25K

+14.87%

Mar 31, 2025

詳細を見る

11.125USD

Dynavax Technologies Corp

11.125

概要

企業名

金融